SG3 Management, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 179 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2021. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.

Quarter-by-quarter ownership
SG3 Management, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q4 2021$194,000
+40.6%
3,7000.0%0.00%0.0%
Q3 2021$138,000
-32.4%
3,700
-26.0%
0.00%
-42.9%
Q2 2021$204,000
-83.4%
5,000
-87.1%
0.01%
-69.6%
Q4 2020$1,230,000
-12.8%
38,680
-29.7%
0.02%
-76.3%
Q2 2020$1,411,00055,0000.10%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2021
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders